BioNTech

BNTX · Nasdaq · Germany

Share price · BNTX

$83.26-9.49 (-10.23%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.2M (1.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when BNTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 28 Aug 2026-8.4%
  2. 19 Aug 2026+22.0%
  3. 21 Apr 2026+6.1%
  4. 11 Mar 2026+8.3%
  5. 10 Mar 2026-17.9%
  6. 2 Feb 2026-4.3%
  7. 21 Jan 2026+11.8%
  8. 13 Jan 2026+4.9%

Share of unusual movement by asset

For each asset, the share of BNTX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Trastuzumab pamirtecan
events and moves
2shown from 8 days
Pumitamig
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—3%
Other company news (earnings, financing, releases naming no asset)—37%
Sessions with no dated event—61%

Assets

(9 total)
9Total Assets
0Approved
4Phase 3 / Filed
5Phase 1–2 / Early
6Diseases
Quick filter:
Showing 9 of 9 assets
Target & Modality
Phase 3
HER3Antibody–drug conjugate
Non-Small Cell Lung CancerBreast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 3
B7-H3Antibody–drug conjugate
Non-Small Cell Lung CancerMetastatic Castration-Resistant Prostate Cancer
Phase 3
PD-L1 and VEGF-AMultispecific antibody
Non-Small Cell Lung CancerSmall Cell Lung Cancer
Phase 3
HER2Antibody–drug conjugate
Breast CancerEndometrial Cancer
HR+/HER2- Metastatic Breast Cancer, HER2-Positive Breast Cancer
Phase 2
Tumor-associated antigens: MAGE-A3, CLDN6, KK-LC-1, PRAME, MAGE-A4Vaccine
Non-Small Cell Lung Cancer
Phase 2
TROP2Antibody–drug conjugate
Non-Small Cell Lung Cancer
Phase 1/2
CD40 x 4-1BB (dual)Monoclonal antibody
Non-Small Cell Lung Cancer
Phase 1
HIV antigensVaccine
HIV
Phase 1
HIV envelopeMonoclonal antibody
HIV

Upcoming events

(44 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
Beruzatatug pelitecanPhase 2NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
Est. primary completion 2026-11 · NCT06107686 · CT.gov ↗
What to watch
2027 (14)
January 2027 (2)
PumitamigPhase 2Neuroendocrine Neoplasm
Est. primary completion 2027-01-01 · NCT05879055 · CT.gov ↗
What to watch
Beruzatatug pelitecanPhase 2Non Small Cell Lung Cancer, Colorectal Cancer, Cervical Cancer, Locally Advanced or Metastatic Solid Tumors
Est. primary completion 2027-01-31 · NCT07202364 · CT.gov ↗
What to watch
May 2027 (2)
PumitamigPhase 2CRC (Colorectal Cancer)
Est. primary completion 2027-05 · NCT07133750 · CT.gov ↗
What to watch
PumitamigPhase 3SCLC
Est. primary completion 2027-05 · NCT06616532 · CT.gov ↗
What to watch
June 2027 (1)
PumitamigPhase 2Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
Est. primary completion 2027-06 · NCT06449209 · CT.gov ↗
What to watch
July 2027 (2)
PumitamigPhase 3Triple Negative Breast Cancer(TNBC)
Est. primary completion 2027-07 · NCT06419621 · CT.gov ↗
What to watch
Beruzatatug pelitecanPhase 2Locally Advanced or Metastatic Breast Cancer
Est. primary completion 2027-07-30 · NCT06439771 · CT.gov ↗
What to watch
August 2027 (2)
Trastuzumab pamirtecanPhase 1/2HER2-positive Advanced Solid Tumor
Est. primary completion 2027-08 · NCT05150691 · CT.gov ↗
What to watch
Sacituzumab drozuntecanPhase 1/2Advanced Solid Tumor
Est. primary completion 2027-08-13 · NCT05438329 · CT.gov ↗
What to watch
November 2027 (1)
PumitamigPhase 1/2Advanced Solid Tumor
Est. primary completion 2027-11 · NCT07147348 · CT.gov ↗
What to watch
December 2027 (4)
Elfetabart drozuntecanPhase 1/2Advanced Solid Tumors
Est. primary completion 2027-12 · NCT05914116 · CT.gov ↗
What to watch
PumitamigPhase 2Pancreatic Ductal Adenocarcinoma (PDAC)
Est. primary completion 2027-12 · NCT07255404 · CT.gov ↗
What to watch
Trastuzumab pamirtecanPhase 3HER2-positive Breast Cancer
Est. primary completion 2027-12 · NCT06265428 · CT.gov ↗
What to watch
Beruzatatug pelitecanPhase 3Locally Advanced or Metastatic Breast Cancer
Est. primary completion 2027-12-31 · NCT07461454 · CT.gov ↗
What to watch
2028 (12)
January 2028 (1)
PumitamigPhase 2Recurrent Glioblastoma
Est. primary completion 2028-01 · NCT07297212 · CT.gov ↗
What to watch
March 2028 (3)
Beruzatatug pelitecan + PumitamigPhase 1/2Advanced Solid Tumor
Est. primary completion 2028-03 · NCT07070232 · CT.gov ↗
What to watch
Trastuzumab pamirtecanPhase 3Endometrial Cancer
Est. primary completion 2028-03 · NCT06340568 · CT.gov ↗
What to watch
PumitamigPhase 2Early-Stage Non-Small Cell Lung Cancer
Est. primary completion 2028-03-15 · NCT07871214 · CT.gov ↗
What to watch
July 2028 (1)
PumitamigPhase 1/2Solid Tumours
Est. primary completion 2028-07-31 · NCT07160725 · CT.gov ↗
What to watch
August 2028 (3)
PumitamigPhase 2Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
Est. primary completion 2028-08 · NCT06449222 · CT.gov ↗
What to watch
PumitamigPhase 2Solid Tumors
Est. primary completion 2028-08-15 · NCT07492680 · CT.gov ↗
What to watch
Beruzatatug pelitecanPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2028-08-31 · NCT07416994 · CT.gov ↗
What to watch
September 2028 (2)
Pumitamig + Elfetabart drozuntecanPhase 1/2Advanced Lung Cancer
Est. primary completion 2028-09 · NCT06892548 · CT.gov ↗
What to watch
PumitamigPhase 2Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
Est. primary completion 2028-09-15 · NCT07680764 · CT.gov ↗
What to watch
October 2028 (1)
PumitamigPhase 2Non-small Cell Lung Cancer
Est. primary completion 2028-10 · NCT06841055 · CT.gov ↗
What to watch
November 2028 (1)
Beruzatatug pelitecan + PumitamigPhase 1/2Non-small Cell Lung Cancer
Est. primary completion 2028-11 · NCT07111520 · CT.gov ↗
What to watch
2029 (8)
January 2029 (2)
PumitamigPhase 2/3Non-small Cell Lung Cancer
Est. primary completion 2029-01 · NCT06712316 · CT.gov ↗
What to watch
PumitamigPhase 1/2Advanced Solid Tumors
Est. primary completion 2029-01-04 · NCT06697197 · CT.gov ↗
What to watch
April 2029 (2)
PumitamigPhase 3Extensive-stage Small-cell Lung Cancer
Est. primary completion 2029-04 · NCT06712355 · CT.gov ↗
What to watch
PumitamigPhase 1/2Relapsed/Refractory Small Cell Lung Cancer
Est. primary completion 2029-04-23 · NCT07325136 · CT.gov ↗
What to watch
August 2029 (1)
Pumitamig + Trastuzumab pamirtecanPhase 1/2Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
Est. primary completion 2029-08 · NCT06827236 · CT.gov ↗
What to watch
October 2029 (1)
PumitamigPhase 1/2Hepatocellular Carcinoma (HCC)
Est. primary completion 2029-10-15 · NCT07291076 · CT.gov ↗
What to watch
November 2029 (1)
PumitamigPhase 1/2Advanced Renal Cell Carcinoma (RCC)
Est. primary completion 2029-11-28 · NCT07293351 · CT.gov ↗
What to watch
December 2029 (1)
PumitamigPhase 3Breast Neoplasms
Est. primary completion 2029-12 · NCT07173751 · CT.gov ↗
What to watch
2030 (5)
February 2030 (1)
PumitamigPhase 2/3Untreated, Unresectable, or Metastatic Colorectal Cancer
Est. primary completion 2030-02-02 · NCT07221357 · CT.gov ↗
What to watch
June 2030 (1)
Est. primary completion 2030-06-30 · NCT06953089 · CT.gov ↗
What to watch
September 2030 (1)
PumitamigPhase 3Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2030-09-18 · NCT07361497 · CT.gov ↗
What to watch
November 2030 (1)
PumitamigPhase 2/3Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Est. primary completion 2030-11-08 · NCT07221149 · CT.gov ↗
What to watch
December 2030 (1)
PumitamigPhase 1/2Metastatic Colorectal Cancer
Est. primary completion 2030-12 · NCT07079631 · CT.gov ↗
What to watch
2031 (4)
February 2031 (2)
Elfetabart drozuntecanPhase 3Metastatic Castration-resistant Prostate Cancer
Est. primary completion 2031-02 · NCT07365995 · CT.gov ↗
What to watch
PumitamigPhase 1/2Lung Cancer, Breast Cancer
Est. primary completion 2031-02-26 · NCT06618287 · CT.gov ↗
What to watch
August 2031 (1)
PumitamigPhase 1/2Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer …
Est. primary completion 2031-08-31 · NCT04895709 · CT.gov ↗
What to watch
October 2031 (1)
PumitamigPhase 3Non-Small Cell Lung Cancer (NSCLC)
Est. primary completion 2031-10-14 · NCT07361510 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 October 2026Topline resultTrastuzumab pamirtecanDYNASTY-Breast02 Phase 3 (NCT06018337) met its primary PFS endpoint vs chemotherapy; the companies call the benefit limited
DualityBio Inc. · Source ↗
28 August 2026Topline resultAutogene cevumeranPhase 2 BNT122-01 (NCT04486378) terminated for futility with overall survival numerical imbalance
BioNTech · Source ↗
9 April 2026Filing acceptedDB-1303NMPA accepts BLA for trastuzumab pamirtecan (DB-1303)
CN, NMPA · DualityBio · Source ↗
Q2 2026PresentationPumitamigROSETTA Lung-02 (NCT06712316) interim Phase 2 data at ASCO 2026: confirmed ORR 57.1% non-squamous, 68.4% squamous

Financial reports

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$3.3B$2.4B$9.0B$322M$517M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$3.0B$2.4B$10.2B$180M$225M operating cash flowreport ↗
2023-FY$4.1B$1.9B$12.9B—$5.8B operating cash flowreport ↗
2022-FY$18.2B$1.6B$14.8B—$14.3B operating cash flowreport ↗
2021-FY$22.5B$1.1B$1.9B—$1.1B operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 27 sales ($89.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-09Sahin Ugur · Chief Executive Officer, 10% ownerOpen-market sale36,209$95.37$3.5MForm 4
2026-10-08Sahin Ugur · Chief Executive Officer, 10% ownerOpen-market sale27,000$92.31$2.5MForm 4
2026-10-07Sahin Ugur · Chief Executive Officer, 10% ownerOpen-market sale24,000$95.86$2.3MForm 4
2026-10-06Sahin Ugur · Chief Executive Officer, 10% ownerOpen-market sale21,000$96.81$2.0MForm 4
2026-10-05Sahin Ugur · Chief Executive Officer, 10% ownerOpen-market sale72,000$97.23$7.0MForm 4
2026-10-02Sahin Ugur · Chief Executive Officer, 10% ownerOpen-market sale17,000$96.72$1.6MForm 4
2026-10-01Sahin Ugur · Chief Executive Officer, 10% ownerOpen-market sale17,000$97.46$1.7MForm 4
2026-09-30Sahin Ugur · Chief Executive Officer, 10% ownerOpen-market sale32,000$98.12$3.1MForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 272 reporting institutions held 47.4M shares ($3.6B, 18.7% of shares outstanding).

#InstitutionSharesValue
1FMR LLC5,709,240$507.4M
2PRIMECAP MANAGEMENT CO/CA/3,793,711$337.2M
3FLOSSBACH VON STORCH SE3,680,315$327.1M
4Dodge & Cox3,676,791$326.8M
5BlackRock, Inc.1,658,153$147.4M
6BNP PARIBAS FINANCIAL MARKETS1,651,789$146.8M
7Temasek Holdings (Private) Ltd1,506,027$133.9M
8CITADEL ADVISORS LLC951,372$84.6M
9BANK OF AMERICA CORP /DE/903,029$80.3M
10GSK plc889,824$79.1M
11BAILLIE GIFFORD & CO882,572$78.4M
12FIRST TRUST ADVISORS LP839,991$74.7M
13UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC783,995$69.7M
14MASSACHUSETTS FINANCIAL SERVICES CO /MA/670,514$59.6M
15Long Focus Capital Management, LLC624,000$55.5M